CYP19A1 and breast cancer: Additional xenograft experiments are required to investigate the role of WEHI-7326 in combination in other breast cancer subtypes such as ER + (with tamoxifen/fulvestrant or aromatase inhibitors) and HER-2 amplified (with Herceptin), but also in BRCA1 mutant BC (with PARP-inhibitor).